Artificial Intelligence
Global Clinical Microbiology Instruments and Reagents Market to Reach $6.1 Billion by 2027
New York, July 28, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Clinical Microbiology Instruments and Reagents Industry” – https://www.reportlinker.com/p05957366/?utm_source=GNW
1 Billion by 2027, growing at aCAGR of 6.4% over the period 2020-2027. Instruments, one of the segments analyzed in the report, is projected to record 5.3% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Reagents segment is readjusted to a revised 7.1% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 7.7% CAGR
The Clinical Microbiology Instruments and Reagents market in the U.S. is estimated at US$1.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$305.3 Million by the year 2027 trailing a CAGR of 7.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 6.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.
Select Competitors (Total 59 Featured)
- 3M
- Abbott Laboratories
- Agilent Technologies
- Becton, Dickinson and Company
- Biomérieux
- Bio-Rad Laboratories, Inc
- Bruker Corporation
- Cepheid Inc
- Danaher Corporation
- Eiken Chemical Co., Ltd.
- Hologic, Inc
- NEOGEN Corporation
- QIAGEN GmbH
- Hoff Man Roche
Diagnostics Division - Shimadzu Corporation
- Thermo Fisher Scientific
Read the full report: https://www.reportlinker.com/p05957366/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
EXHIBIT 1: The World of Clinical Microbiology Gains Sudden
Prominence as Scientists Mobilize United Efforts to Find Ways
to Detect, Treat & Vaccinate People Against the Novel
Coronavirus: Global Scale of Daily Testing Vs Confirmed
Cases Per Million
Clinical Microbiology: An Introduction
Outlook: Evolutionary Battle against Microbes Drives Market Future
Instant Detection of Pathogens : A New Epoch in the Fight for
Survival
Reagents Account for Major Share
Asia-Pacific Drives Future Growth
Recent Market Activity
World Brands
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Microbiology Laboratories Switch to Automation to Push Yields
EXHIBIT 2: World Laboratory Automation Market in US$ Billion
for Years 2018, 2020, 2022, 2024 & 2026
Clinical Microbiology Market Benefits from Digitalization and
Robotization Trend
Integration of Clinical Microbiology with Cloud Computing
Artificial Intelligence Holds Positive Implications for
Automation of Clinical Microbiology
Advancements in Molecular Diagnostics Drive Market Growth
Emerging Technologies in Clinical Microbiology Diagnostics Aim
at Faster Diagnosis
Technological Advances Crucial to Sustain Future Market Growth
Rapid Diagnostics Bring in a Transformation
Automated and Rapid Microbiological Tests Revolutionize
Microbiological Testing
Traditional Rapid Microbiological Tests Make Way for New, Probe
Tests
Antibiotic Resistant Bacteria Throws the Spotlight on Microbial
Testing
Research in Stem Cell Technology, and Regenerative Medicine
Expand Growth Opportunities
EXHIBIT 3: Stem Cell Banking Global Market Estimates and
Forecasts in US$ Billion: 2020, 2022 & 2024
Greater Number of Tests for HIV and Sexually Transmitted
Diseases Amplify Growth
EXHIBIT 4: Global HIV Prevalence: Number of People Living with
AIDs (in Thousands) by Region for 2018
EXHIBIT 5: Number of AIDS-Related Deaths (in Thousands) by
Region for 2018
Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer
Disease
Home HIV Testing Emerges as a Lucrative Option
Increasing Incidence of Infectious Diseases Drives Growth
EXHIBIT 6: Infectious Diseases Remain Major Cause of Death in
Under Developed Regions: Breakdown of Leading Causes of Death
in Sub-Saharan Africa (in %)
EXHIBIT 7: Infectious Diseases Related Mortality High Among
Children Below 5 Years: Breakdown of Leading Causes of Death
in Children Below 5 Years (in %)
Increasing Prevalence of Respiratory Infections Drive Growth
EXHIBIT 8: Global Number of Deaths Caused Due to Communicable
Diseases (In 000s)
Influenza Boosts Rapid Test Prospects
EXHIBIT 9: Flu Related CDC Estimates from October 2019-April4,
2020
Rise in Prevalence of COPD Augments Demand
EXHIBIT 10: Global Prevalence of COPD by Age Group: Percentage
of Men and Women Affected by the Condition
Rise in Pollution Levels Trigger Increase in Respiratory Diseases
EXHIBIT 11: World Ranking of Most Polluted Countries: 2019
EXHIBIT 12: Percentage Share Breakdown of Global Deaths Linked
to Air Pollution
Increase in Healthcare Spending in Emerging Markets to Propel
Demand
EXHIBIT 13: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
Demographic Shifts & Societal Changes Drive Demand for Test
Volumes
EXHIBIT 14: Elderly Healthcare Expenditure as a % of GDP
EXHIBIT 15: Global Population Statistics for the 65+ Age Group
in Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
EXHIBIT 10: Life Expectancy at Age 60 and 80 Years: (2010-2015
), (2020-2025) & (2045-2050)
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Clinical Microbiology
Instruments and Reagents by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Geographic Region – Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Instruments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 5: World Historic Review for Instruments by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Instruments by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Reagents by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 8: World Historic Review for Reagents by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 9: World 15-Year Perspective for Reagents by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Respiratory
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Respiratory Diseases by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Respiratory Diseases by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Bloodstream
Infections by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Bloodstream Infections by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Bloodstream Infections
by Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Gastrointestinal
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Gastrointestinal Diseases
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Gastrointestinal
Diseases by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 19: World Current & Future Analysis for Sexually
Transmitted Diseases by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Sexually Transmitted
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Sexually Transmitted
Diseases by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 22: World Current & Future Analysis for Urinary Tract
Infections by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Urinary Tract Infections by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 24: World 15-Year Perspective for Urinary Tract
Infections by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 25: World Current & Future Analysis for Other Disease
Areas by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 26: World Historic Review for Other Disease Areas by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 27: World 15-Year Perspective for Other Disease Areas by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 28: World Current & Future Analysis for Hospitals &
Diagnostic Centers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 29: World Historic Review for Hospitals & Diagnostic
Centers by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 30: World 15-Year Perspective for Hospitals & Diagnostic
Centers by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 31: World Current & Future Analysis for Custom Lab
Service Providers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 32: World Historic Review for Custom Lab Service
Providers by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 33: World 15-Year Perspective for Custom Lab Service
Providers by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 34: World Current & Future Analysis for Academic &
Research Institutes by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 35: World Historic Review for Academic & Research
Institutes by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 36: World 15-Year Perspective for Academic & Research
Institutes by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
III. MARKET ANALYSIS
UNITED STATES
Market Overview
EXHIBIT 16: Healthcare Spending as a % of GDP in the US: 2010-2020
COVID-19 Pandemic: US Emerges as a Major Market for COVID-19 Tests
Table 37: USA Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 38: USA Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 39: USA 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027
Table 40: USA Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 41: USA Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 42: USA 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027
Table 43: USA Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 44: USA Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 45: USA 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027
CANADA
Table 46: Canada Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 47: Canada Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 48: Canada 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027
Table 49: Canada Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 50: Canada Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 51: Canada 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027
Table 52: Canada Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 53: Canada Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 54: Canada 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027
JAPAN
Market Overview
Covid-19 Testing Market in Japan
Demographics Drive Market Growth
EXHIBIT 17: Breakdown of Population by Age Group in Japan:
2010, 2020, and 2025
Market Analytics
Table 55: Japan Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 56: Japan Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 57: Japan 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027
Table 58: Japan Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 59: Japan Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 60: Japan 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027
Table 61: Japan Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 62: Japan Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 63: Japan 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027
CHINA
Market Overview
Covid-19 Testing Market
Market Analytics
Table 64: China Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 65: China Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 66: China 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027
Table 67: China Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 68: China Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 69: China 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027
Table 70: China Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 71: China Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 72: China 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027
EUROPE
Market Overview
COVID-19 Pandemic Propels Demand
Growth in Clinical Diagnostics Automation
Rise in Automated, and Rapid Tests in Clinical Applications
Ageing Demography: An Opportunity Indicator
Market Analytics
Table 73: Europe Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Geographic Region –
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 74: Europe Historic Review for Clinical Microbiology
Instruments and Reagents by Geographic Region – France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 75: Europe 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Geographic Region – Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Table 76: Europe Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 77: Europe Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 78: Europe 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027
Table 79: Europe Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 80: Europe Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 81: Europe 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027
Table 82: Europe Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 83: Europe Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 84: Europe 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027
FRANCE
Table 85: France Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 86: France Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 87: France 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027
Table 88: France Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 89: France Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 90: France 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027
Table 91: France Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 92: France Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 93: France 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027
GERMANY
Table 94: Germany Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 95: Germany Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 96: Germany 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027
Table 97: Germany Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 98: Germany Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05957366/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Artificial Intelligence
Akuvox S567G Smart Indoor Monitor Has Received Google Mobile Service Certification
XIAMEN, China, Sept. 13, 2024 /PRNewswire/ — Akuvox has announced its S567G, an indoor monitor powered by Android™, to have received Google GMS certification. This certification ensures full support for Google Services, allowing users to download and update apps directly from the Google Play Store, including smart home control apps. It also enhances system security, protecting against malware and unauthorized access.
GMS certification involves comprehensive testing and approval by Google or a designated 3PL lab, validating security and compatibility to ensure seamless integration within the Android ecosystem. Receiving GMS certification underscores Akuvox’s leadership in the smart intercom industry. Building on its legacy as the pioneer of Android smart intercoms, Akuvox continues to elevate its Android systems with Google’s rigorous certification, offering clients flexible and sophisticated smart intercom solutions.
The S567G’s GMS certification ensures flawless operation with key Google apps like Chrome, Gmail, YouTube, Maps, and the Play Store. Edward Shi, Product Manager of the S567G, notes, “The positive feedback we’ve received from clients, even during testing, confirms that this device is transforming daily life. It’s more than just an intercom — it’s a versatile tool, even capable of functioning as a small TV. Our team has worked tirelessly to meet the highest standards, and I’m excited to see how it enhances smart living for our users.”
The S567G’s features extend beyond intercom functionality. With four HD speakers and a 1280 x 800 IPS LCD screen, it offers an exceptional audio-visual experience, redefining the concept of an indoor monitor. Whether for entertainment or smart home control, the S567G stands out as a versatile wall-mounted tablet, bringing innovation to every interaction.
About Akuvox
Akuvox is a global leading provider of smart intercom and smart home products and solutions. It is committed to unleashing the power of technology to improve people’s lives with better communication, greater security, and more convenience. Encompassing artificial intelligence, SIP, Android, cloud, security, and other advanced technologies, Akuvox continuously drives breakthrough changes in the industry and creatively delivers an unrivaled portfolio of smart intercom and smart home products and solutions. It has been deployed and used daily in more than 110 countries and regions, meeting customer needs in various vertical markets that range from residential to commercial, from healthcare to public safety.
Photo – https://mma.prnewswire.com/media/2504901/Akuvox_S567G_Indoor_Monitor_Has_Received_GMS_CertificationAkuvox_proudly_announced.jpg
View original content:https://www.prnewswire.co.uk/news-releases/akuvox-s567g-smart-indoor-monitor-has-received-google-mobile-service-certification-302248219.html
Artificial Intelligence
SeaBubbles Accelerates Sustainable Maritime Mobility with SmartBubble and Strategic Acquisition
SAINT JORIOZ, France, Sept. 13, 2024 /PRNewswire/ — SeaBubbles, French pioneer in zero-emission hydrofoils, strengthens its commitment to ecological transition with the launch of SmartBubble, new flying boat model combining cutting-edge technology with iconic design. This innovative vessel, designed to carry up to eight people at a speed of 16 knots (30 km/h), takes its passengers on a silent and environmentally friendly flight, ideal for water taxi services and urban transportation.
SmartBubble: Concentration of Technology and Design
Following the success of its first public line on Lake Annecy, where hundreds of passengers experienced the unique sensation of flying aboard The Bubble (4-seater model), SeaBubbles reaches a new milestone with the homologation of the SmartBubble (8-seater model) and its four patents, including retractable foils.
SmartBubble technology is geared towards energy efficiency. The submerged wings (foils) equipped with automatic flaps allow to fly at low speeds, saving 40% of energy required. This unique boat has just been presented afloat for the first time at the Cannes Yachting Festival.
SeaBubbles Strengthens Flight Control Expertise with Neocean Acquisition
SeaBubbles also announces the acquisition of Neocean technology, to accelerate the development of flight control expertise, specifically on “inverted T” foils. Neocean is renowned for developing the Overboat, foiling catamaran with proven stability and maneuverability.
SeaBubbles is a key player in hydrofoil navigation, technology that improves energy efficiency of boats, particularly electric ones. The flight control system is a central element of the flight experience: it is designed to ensure stable flight by dynamically and autonomously managing the mechanical inclination of the flaps on the trailing edges of the foils.
SeaBubbles: Vision for the Future
SeaBubbles’ ambition is to revolutionize urban and suburban maritime transport with more efficient and environmentally friendly boats. Examples such as the Calanques National Park, Norwegian fjords, alpine lakes or the canals of Amsterdam demonstrate a committed initiative towards the preservation of aquatic ecosystems by gradually banning the circulation of thermal boats.
“Foils significantly reduce the drag of our boats, allowing our hydrofoils to move more easily and with less energy than a conventional boat: a considerable gain in cost and energy,” explains Virginie Seurat, CEO of SeaBubbles. “The acquisition of Neocean marks a decisive turning point and prepares us for our industrialization phase. We are ready to redefine the pleasure of boating and offer boats that comply with increasingly stringent environmental standards, while offering unique sailing comfort – zero noise, zero waves, zero emissions.”
AxiCom for SeaBubbles, [email protected]
Photo – https://mma.prnewswire.com/media/2505216/SmartBubble_SeaBubbles.jpgLogo – https://mma.prnewswire.com/media/2146226/SeaBubbles_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/seabubbles-accelerates-sustainable-maritime-mobility-with-smartbubble-and-strategic-acquisition-302247900.html
Artificial Intelligence
Amagi and BuyDRM Partner to Secure Streaming Video on PlayMedia’s FAST Platform GoPlay
NEW YORK, Sept. 13, 2024 /PRNewswire/ — Amagi, the global leader in cloud-based SaaS technology for broadcast and connected TV (CTV), today announced a partnership with BuyDRM, a leading content security services and solutions provider offering cloud-based content security for the streaming video platform GoPlay by PlayMedia. This successful collaboration with BuyDRM’s KeyOS Content Security Platform provides robust safeguards for valuable video content while allowing PlayMedia to focus on delivering high-quality video experiences to its audience without compromising security.
This partnership marks a significant step forward in addressing the evolving challenges of content security in today’s digital landscape. By combining BuyDRM’s expertise in DRM solutions with Amagi’s scalable cloud infrastructure, PlayMedia can ensure comprehensive protection for its content library against piracy and unauthorized access.
BuyDRM’s KeyOS Content Security Platform is an award-winning, studio-approved multi-DRM and watermarking content security platform for video. The KeyOS platform protects the assets of copyright holders and distributors with robust security services and solutions for high-value video content and is trusted by many of the most prominent names in media and entertainment across the globe.
Srinivasan KA, Co-Founder and Chief Revenue Officer at Amagi, said, “Our partnership with BuyDRM aligns perfectly with our endeavor to empower content creators and distributors with innovative technology. Integrating BuyDRM’s KeyOS platform into our cloud-based platform offers our customers like PlayMedia the peace of mind they need to focus on delivering exceptional content.”
“The alliance with Amagi made it possible for our mutual customer, PlayMedia, to utilize our content security offering in a cloud-based environment without sacrificing their security standards and the user experience,” said Christopher Levy, BuyDRM CEO and Co-Founder. “Both companies worked hard to empower PlayMedia with the technology needed to thrive in today’s streaming market.”
Amagi provides a complete suite of channel creation, distribution, and monetization solutions. The company’s clients include some of the world’s biggest names, including A+E Networks UK, ABS-CBN, Astro, Cox Media Group, DAZN, Globo, Lionsgate Studio, NBCUniversal, Tastemade, and VIZIO.
Amagi is exhibiting at IBC2024. Attendees can join Amagi and experience its innovative media cloud platform, which addresses unified broadcast and streaming TV workflows. Click here to book a meeting with Amagi executives.
About Amagi
Amagi is a next-generation media technology company that provides cloud broadcast and targeted advertising solutions to broadcast TV and streaming TV platforms. Amagi enables content owners to launch, distribute, and monetize live, linear channels on Free Ad-supported Streaming TV and video services platforms. Amagi also offers 24×7 cloud-managed services, bringing simplicity, advanced automation, and transparency to all broadcast operations. Overall, Amagi supports 800+ content brands, 800+ playout chains, and 5,000+ channel deliveries on its platform in over 150 countries. Amagi has a presence in New York, Los Angeles, Toronto, Mexico City, London, Paris, Sydney, Seoul, and Singapore, broadcast operations in New Delhi, and innovation centers in Bengaluru, Zagreb, and Łódź.
About BuyDRM
BuyDRM™ is a leading global provider of content security services for the entertainment, education, enterprise, and hospitality industries. BuyDRM’s KeyOS content security platform powers many of the largest brands in media and technology. With decades of market-leading experience implementing commercial content security solutions and media technologies, BuyDRM has amassed substantial success stories for many of today’s largest brands such as ABC (Australian Broadcasting Corporation), Daily Rounds, Deluxe Digital, EPIX, FuboTV, POPS Singapore, Rakuten Viki, Redbox, Roku, Samsung TV+, SBS Australia, Showtime, Sinclair Digital, Soundcloud, Sportradar, TubiTV and ViaPlay.
For more information, please visit www.buydrm.com.
Amagi Contact:
Aashish WashikarDirector – Corporate Communications Email: [email protected]
Photo: https://mma.prnewswire.com/media/2505092/Amagi_BuyDRM.jpg
View original content:https://www.prnewswire.co.uk/news-releases/amagi-and-buydrm-partner-to-secure-streaming-video-on-playmedias-fast-platform-goplay-302247802.html
-
Artificial Intelligence3 days agoManulife-backed Serverfarm acquires two data centers providing over 500MW of new potential capacity in the Houston market
-
Artificial Intelligence3 days agoEnhanced Security for Alpha Bank Romania Customers: New Anti-Fraud System Developed with Montran
-
Artificial Intelligence2 days agoAtento Reaffirms Leadership in Frost & Sullivan’s Ranking as a Leader in CX Management in 2024
-
Artificial Intelligence2 days agoNTT TechnoCross Recognized with Frost & Sullivan’s 2024 Company of the Year Award for Leading Innovation in Japanese Privileged Access Management Solutions
-
Artificial Intelligence3 days agoRetail golden quarter: how AI can boost sales success for retailers
-
Artificial Intelligence3 days ago
Global Health Exhibition Announces Opportunity for Healthcare Startups to secure over 100,000 SAR in Vision NextGen Competition Designed to Fast-Track Health Innovations
-
Artificial Intelligence3 days agoeQ Technologic Appoints New CEO, Kunal Khaladkar, to Continue to Drive Business Strategy and Innovation
-
Artificial Intelligence3 days agoData quality takes centre stage as 70 senior data leaders set to gather at CDO BFSI Exchange 2024
